Technology | September 08, 2014

FDA Clears Low-profile Brain Stent

MicroVention LVIS Stent FDA Clearance July 2014

September 8, 2014 — The U.S, Food and Drug Administration (FDA) has cleared MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.), which is a stent and delivery system used to treat certain brain aneurysms.

The stent is a self-expanding, nickel-titanium (nitinol) single wire braid. The delivery system consists of an introducer and delivery wire and is used to deliver the stent to the aneurysm. The stent keeps the soft platinum coils that are put into the aneurysm from slipping back into the main blood vessel.

The LVIS Device is intended for use with soft platinum coils for the treatment of unruptured, wide-neck brain (intracranial, saccular) aneurysms. The stent serves two functions. One, it supports the coils so they block the aneurysm and two, the stent prevents the coils from slipping back into the main blood vessel.

How it works:

  • Using a guidewire, a small catheter (microcatheter) is advanced into the blood vessel along the aneurysm.
  • The guidewire is removed and the microcatheter remains in place allowing for the proper insertion of the LVIS device.
  • The physician positions the device to be released (deployed) and carefully retracts the microcatheter. The physician then advances the delivery wire allowing the LVIS device to be deployed across the neck of the aneurysm.
  • The stent expands as it exits the microcatheter.
  • After the microcatheter is positioned in the aneurysm, soft platinum coils are delivered into the aneurysm to block the flow of blood into the aneurysm.
  • The LVIS device serves as a support for the coils to prevent them from moving back into the blood vessel.

 

The LVIS Device should not be used in:

  • Patients who cannot take medications that thin the blood and prevent blood clots.
  • Patients with known hypersensitivity to metal, such as nickel-titanium and metal jewelry. Patients with anatomy that does not allow passage or deployment of the LVIS device.
  • Patients with an active bacterial infection.
  • Patients with a pre-existing stent in place at the target aneurysm.

 

For more information: www.accessdata.fda.gov/cdrh_docs/pdf13/H130005a.pdf

 

 

 

 

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Overlay Init